Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control
Overview
- Phase
- Phase 1
- Intervention
- B Low Dose GIK
- Conditions
- Glycemic Control
- Sponsor
- American Heart Association
- Enrollment
- 250
- Locations
- 1
- Primary Endpoint
- glycemic control
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This study seeks to determine whether varying the dose of insulin and glucose in diabetic patients during coronary bypass surgery will improve outcomes in these patients.
Detailed Description
Our previous study has shown that maintaining serum glucose between 120-180mg/dl in the perioperative period during CABG surgery in diabetic patients improves outcomes. The purpose of this trial is: (1) to determine whether outcomes can be improved by altering the content of glucose or insulin in these solutions (2)to determine the effect of these solutions and glycemic control on the inflammatory response of arterial and venous conduits used during surgery, (3) to determine whether the beneficial effects of improved glycemic control can be correlated with changes in the inflammatory response.
Investigators
Harold L. Lazar MD
Professor of Cardiothoracic Surgery
American Heart Association
Eligibility Criteria
Inclusion Criteria
- •Diabetic CABG patients
Exclusion Criteria
- •Renal and hepatic failure
Arms & Interventions
B Low dose GIK
This group will have low doses of glucose and insulin
Intervention: B Low Dose GIK
C High Dose GIK
This group will have high doses of insulin and glucose
Intervention: C High Dose GIK
A Insulin
This group will receive only an intravenous insulin infusion
Intervention: A IV Insulin drip
Outcomes
Primary Outcomes
glycemic control
Time Frame: 24 hours following surgery
glycemic control, postoperative morbidity, inflammatory markers
Time Frame: 24 hours following surgery
Secondary Outcomes
- free fatty acid levels(24 hours following surgery)